Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 23.
doi: 10.1038/s41541-026-01377-0. Online ahead of print.

Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge

Lanlan Dong #  1   2 , Nan Gao #  3 , Renqiang Liu #  4 , Kangli Cao  1 , Ai Xia  1   2 , Tianhan Yang  2 , Xinghao Pan  5 , Cuisong Zhu  2 , Ziling Zhang  1 , Dongming Zhao  6 , Chen Zhao  7 , Xiaoyan Zhang  8   9 , Jianqing Xu  10   11   12
Affiliations

Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge

Lanlan Dong et al. NPJ Vaccines. .

Abstract

The African Swine Fever Virus (ASFV) poses a major threat to global livestock production by infecting both domestic and wild pigs, causing significant economic loss. Despite promising protective results observed with live attenuated viruses, the safety concern blocked its extensive application. In this study, we developed a novel vaccine combining two recombinant vaccinia viruses-rTTV-D-A and rTTV-K-J-that together express eight ASFV genes, including EP402R (CD2v), B646L (p72), B602L (pB602L), D117L (p17), H240R (pH240R), B438L (p49), E183L (p54), CP204L (p30), and a synthetic T antigen composed of conserved T cell epitopes from multiple ASFV proteins, aiming to induce both humoral and T-cell immune responses against different viral antigens. After demonstrating that this vaccine induced antigen-specific humoral and cellular responses in both mice and swine, its protective efficacy in swine was examined using a lethal challenge model. The vaccinated pigs showed a promising protection against the lethal challenge of a virulent genotype II ASFV strain (100 HAD50/pig), with 4 out of 6 surviving, while all control animals succumbed from 9 to 15 days post challenge. Importantly, the protection was further evidenced by the recovery to normal temperature and no ASFV infection-related clinical signs or virus shedding in surviving pigs over a 21-day observation period. Our results support the potential of rTTV-D-A and rTTV-K-J as a novel multi-immunogen vaccinia-vectored ASFV vaccine. Further studies are warranted to explore and improve its use as a standalone vaccine or in combination with other vaccine platforms to achieve broad and effective protection against ASFV.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Patent applications related to this work have been filed in China (application number: 202411253959.6) and internationally under the Patent Cooperation Treaty (application number: PCT/CN2024/117421), with J.X., X.Z., and L.D. listed as inventors. All other authors declare no competing interests.

References

    1. Blome, S., Franzke, K. & Beer, M. African swine fever–A review of current knowledge. Virus Res. 287, 198099 (2020).
    1. Kleiboeker, S. B. & Scoles, G. A. Pathogenesis of African swine fever virus in Ornithodoros ticks. Anim. Health Res. Rev. 2, 121–128 (2001).
    1. Pereira De Oliveira, R. et al. Differential vector competence of Ornithodoros soft ticks for African swine fever virus: what if it involves more than just crossing organic barriers in ticks? Parasites Vectors 13, 1–15 (2020).
    1. Li, Z. et al. African swine fever virus: a review. Life 12, 1255 (2022).
    1. Ruedas-Torres, I., Thi to Nga, B. & Salguero, F. J. Pathogenicity and virulence of African swine fever virus. Virulence 15, 2375550 (2024).